Of the growing list of actionable drug–gene associations, one of the most well-validated is the interaction between solute carrier organic anion transporter family member 1B1 (SLCO1B1) and statin-associated muscle symptoms (SAMS) [6,7,8]. The gene discussed is SLCO1B1; the disease is short stature-auditory canal atresia-mandibular hypoplasia-skeletal anomalies syndrome.